Navigation Links
Compound may provide drug therapy approach for Huntington's disease
Date:6/23/2011

DALLAS June 23, 2011 UT Southwestern Medical Center researchers have identified compounds that appear to inhibit a signaling pathway in Huntington's disease, a finding that may eventually lead to a potential drug therapy to help slow the progression of degenerative nerve disorders.

"Our studies have uncovered a new therapeutic target for Huntington's disease treatment and possibly for other neurodegenerative diseases," said Dr. Ilya Bezprozvanny, professor of physiology and senior author of the study, published in today's issue of Chemistry and Biology. "In addition, we now have this new series of compounds that gives us a tool to study the pathogenesis of Huntington's disease."

Huntington's disease is a fatal genetic disorder in which certain brain cells waste away. More than 250,000 people in the U.S. have the disorder or are at risk for it. The most common form is adult-onset, with symptoms usually developing in patients in their mid-30s and 40s.

The disease results in uncontrolled movements, psychiatric disturbance, gradual dementia and eventually death. There is no therapy available currently to slow the progression of the disease.

Scientists at UT Southwestern found that quinazoline-derived compounds effectively block what is known as the store-operated calcium entry signaling pathway, which was never before implicated in Huntington nerve cells but that might be a therapeutic target in the disease.

Dr. Bezprozvanny's laboratory research has contributed to growing scientific evidence that suggests abnormalities in neuronal calcium signaling play an important role in the development of Huntington's disease. UT Southwestern researchers demonstrated in the current study that the quinoline compounds supplied by EnVivo protected brain cells.

"If this holds, this compound can be considered to have potential therapeutic application for Huntington's," he said. "As we ultimately seek a cure, we are encouraged to have found something that may slow the progress or delay the onset of the disease."


'/>"/>

Contact: Robin Russell
robin.russell@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related biology news :

1. Toxic compounds in groundwater
2. TGen study identifies compounds that could slow down Alzheimers disease
3. Mushroom compound suppresses prostate tumors
4. Scientists find new class of compounds with great potential for research and drug development
5. URI scientist discovers 54 beneficial compounds in pure maple syrup
6. New data published in Nature Genetics demonstrate that tiny LNA-based compounds developed by Santaris Pharma A/S inhibit entire disease-associated microRNA families
7. Rockefeller Scientists discover new compound that rids cells of Alzheimer protein debris
8. Compound useful for studying birth defects may also have anti-tumor properties
9. Chemical compounds in trees can fight deadly staph infections in humans
10. Antifungal compound found on tropical seaweed has promising antimalarial properties
11. UT researchers link algae to harmful estrogen-like compound in water
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 2017  It sounds simple and harmless—an electronic ... vital signs and alerts parents on their smart ... level drops. But pediatric experts argue that such ... no evidence of medical benefits, especially to healthy ... to parents of healthy babies, promising peace of ...
(Date:1/19/2017)... PORTLAND, Oregon and PUNE, India , January 19, ... Market Research, titled, "Global Biometric Sensor Market, Opportunities and Forecast, 2014 - ... 2022, growing at a CAGR of 9.6% from 2016 to 2022. In 2015, ... share owing to high-level security for both public and private sectors. ... ...
(Date:1/18/2017)... MINNETONKA, Minn. , Jan. 18, 2017 /PRNewswire/ ... eClinical technology company that supports the entire spectrum ... 2016 has been another record-breaking year for the ... and market interest in MedNet,s eClinical products and ... to the tremendous marketplace success of ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... SAN FRANCISCO , Feb. 24, 2017 ... that is developing a new category of therapeutics, announced ... trial of SB-030 in peripheral artery disease. The trial ... locally administered single-use therapeutic, in the reduction of restenosis ... reached this critical development milestone for SB-030," said ...
(Date:2/24/2017)... China Cord Blood Corporation (NYSE: CO ) ... blood collection, laboratory testing, hematopoietic stem cell processing and ... results for the third quarter and first nine months ... Third Quarter of Fiscal 2017 Highlights ... increased by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... -- China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or ... China, today announced its financial results for the fourth quarter ... 2016 Financial Highlights Total sales in ... terms, or increased by 13.6% in USD terms to $77.6 ... Gross profit increased by 13.3% to $46.8 ...
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ("OncoSec") ... will host a Key Opinion Leader event to highlight ... oral and poster presentation at the upcoming 2017 ASCO-SITC ... KOL event will be held in-person and via live ... / 9:00 AM PST at the Lotte New York ...
Breaking Biology Technology: